Pantothenate Kinase-Associated Neurodegeneration (PKAN) and PLA2G6-Associated Neurodegeneration (PLAN). Review of Two Major Neurodegeneration with Brain Iron Accumulation (NBIA) Phenotypes

International Review of Neurobiology

Volumn 110, Issue , 2013, Pages 49-71

  Kurian, Manju A ^a,b   Hayflick, Susan J ^c,d,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Neurodegeneration with brain iron accumulation (NBIA); PANK2; PLA2G6

Indexed keywords

DEFERIPRONE; PANTOTHENIC ACID;

ARTICLE; BRAIN ELECTROPHYSIOLOGY; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; HUMAN; IMAGE ANALYSIS; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; MUTATOR GENE; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; PANK2 GENE; PHENOTYPE; PLA2G6 ASSOCIATED NEURODEGENERATION; PRIORITY JOURNAL; SPASTICITY; SYMPTOM; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

NEURODEGENERATION WITH BRAIN IRON ACCUMULATION (NBIA); PANK2; PLA2G6;

ANIMALS; BRAIN; GROUP VI PHOSPHOLIPASES A2; HUMANS; IRON METABOLISM DISORDERS; MUTATION; NEUROAXONAL DYSTROPHIES; PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION; PHENOTYPE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 84887245377     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-410502-7.00003-X     Document Type: Chapter

References (71)

1. Abbruzzese G., Cossu G., Balocco M., Marchese R., Murgia D., Melis M., et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 2011, 96:1708-1711.
2. Baburina I., Jackowski S. Cellular responses to excess phospholipid. Journal of Biological Chemistry 1999, 274:9400-9408.
3. Balsinde J., Balboa M.A. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cellular Signalling 2005, 17:1052-1062.
4. Baumeister F.A., Auer D.P., Hortnagel K., Freisinger P., Meitinger T. The eye-of-the-tiger sign is not a reliable disease marker for Hallervorden-Spatz syndrome. New England Journal of Medicine 2005, 348:33-40.
5. Benke T., Butterworth B. Palilalia and repetitive speech: Two case studies. Brain and Language 2001, 78:62-81.
6. Benke T., Hohenstein C., Poewe W., Butterworth B. Repetitive speech phenomena in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 2000, 69:319-324.
7. Bower M.A., Bushara K., Dempsey M.A., Das S., Tuite P.J. Novel mutations in siblings with later-onset PLA2G6-associated neurodegeneration (PLAN). Movement Disorders 2011, 26:1768-1769.
8. Brunetti D., Dusi S., Morbin M., Uggetti A., Moda F., D'Amato I., et al. Pantothenate kinase-associated neurodegeneration: Altered mitochondria membrane potential and defective respiration in Pank2 knock-out mouse model. Human Molecular Genetics 2012, 21:5294-5305.
9. Carrilho I., Santos M., Guimarães A., Teixeira J., Chorão R., Martins M., et al. Infantile neuroaxonal dystrophy: What's most important for the diagnosis?. European Journal of Paediatric Neurology 2008, 12:491-500.
10. Castelnau P., Cif L., Valente E.M., Vayssiere N., Hemm S., Gannau A., et al. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Annals of Neurology 2005, 57:738-741.
11. Chiapparini L., Savoiardo M., D'Arrigo S., Reale C., Zorzi G., Zibordi F., et al. The "eye-of-the-tiger" sign may be absent in the early stages of classic pantothenate kinase associated neurodegeneration. Neuropediatrics 2011, 42:159-162.
12. Ching K.H., Westaway S.K., Gitschier J., Higgins J.J., Hayflick S.J. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology 2002, 58:1673-1674.
13. Crompton D., Rehal P.K., MacPherson L., Foster K., Lunt P., Hughes I., et al. Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: Implications for molecular diagnosis. Molecular Genetics and Metabolism 2010, 100:207-212.
14. del Valle-López P., Pérez-García R., Sanguino-Andrés R., González-Pablos E. Adult onset Hallervorden-Spatz disease with psychotic symptoms. Actas Españolas de Psiquiatría 2011, 39:260-262.
15. Delgado R.F., Sanchez P.R., Speckter H., Then E.P., Jiminez R., Oviedo J., et al. Missense PANK2 mutation without "eye of the tiger" sign: MR findings in a large group of patients with pantothenate kinase-associated neurodegeneration (PKAN). Journal of Magnetic Resonance Imaging 2012, 35:788-794.
16. Dooling E.C., Schoene W.C., Richardson E.P. Hallervorden-Spatz syndrome. Archives of Neurology 1974, 30:70-83.
17. Egan R.A., Weleber R.G., Hogarth P., Gregory A., Coryell J., Westaway S.K., et al. Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome). American Journal of Ophthalmology 2005, 140:267-274.
18. Engel L.A., Jing Z., O'Brien D.E., Sun M., Kotzbauer P.T. Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism. PLoS One 2010, 5:e12897.
19. Farina L., Nardocci N., Bruzzone M.G., D'Incerti L., Zorzi G., Verga L., et al. Infantile neuroaxonal dystrophy: Neuroradiological studies in 11 patients. Neuroradiology 1999, 41:376-380.
20. Freeman K., Gregory A., Turner A., Blasco P., Hogarth P., Hayflick S. Intellectual and adaptive behavior functioning in pantothenate kinase-associated neurodegeneration. Journal of Intellectual Disability Research 2007, 51:417-426.
21. Gregory A., Hayflick S.J. Pantothenate kinase-associated neurodegeneration. GeneReviews™ [Internet] 2002, University of Washington, Seattle, WA, (updated 2013 January 31). R.A. Pagon, M.P. Adam, T.D. Bird, C.R. Dolan, C.T. Fong, K. Stephens (Eds.).
22. Gregory A., Hayflick S.J. Neurodegeneration with brain iron accumulation disorders overview. GeneReviews™ [Internet] 2013, University of Washington, Seattle, Seattle, WA. R.A. Pagon, M.P. Adam, T.D. Bird, C.R. Dolan, C.T. Fong, K. Stephens (Eds.).
23. Gregory A., Kurian M.A., Maher E.R., Hogarth P., Hayflick S.J. PLA2G6-associated neurodegeneration. GeneReviews™ [Internet] 2008, University of Washington, Seattle, WA, (updated 2012 April 19). R.A. Pagon, M.P. Adam, T.D. Bird, C.R. Dolan, C.T. Fong, K. Stephens (Eds.).
24. Gregory A., Polster B.J., Hayflick S.J. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. Journal of Medical Genetics 2009, 46:73-80.
25. Gregory A., Westaway S.K., Holm I.E., Kotzbauer P.T., Hogarth P., Sonek S., et al. Neurodegeneration associated with genetic defects in phospholipase A2. Neurology 2008, 71:1402-1409.
26. Guimaraes J., Santos J.V. Generalized freezing in Hallervorden-Spatz syndrome: Case report. European Journal of Neurology 1999, 6:509-513.
27. Hallervorden J. Uber eine familiare Erkrankung im extrapyramidalen System. Deutsche Zeitschrift für Nervenheilkunde 1924, 81:204-210.
28. Hartig M.B., Hortnagel K., Garavaglia B., Zorzi G., Kmiec T., Klopstock T., et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Annals of Neurology 2006, 59:248-256.
29. Hayflick S.J., Penzien J.M., Michl W., Sharif U.M., Rosman N.P., Wheeler P.G. Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatric Neurology 2001, 25:166-169.
30. Hayflick S.J., Westaway S.K., Levinson B., Zhou B., Johnson M.A., Ching K.H., et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. New England Journal of Medicine 2003, 348:33-40.
31. Hogarth P., Gregory A., Kruer M.C., Sanford L., Wagoner W., Natowicz M.R., et al. New form of neurodegeneration with brain iron accumulation: Features associated with MPAN. Neurology 2013, 80:268-275.
32. Houlden H., Lincoln S., Farrer M., Cleland P.G., Hardy J., Orrell R.W. Compound heterozygous PANK2 mutations confirm HARP and Hallervorden-Spatz syndromes are allelic. Neurology 2003, 61:1423-1426.
33. Isaac C., Wright I., Bhattacharyya D., Baxter P., Rowe J. Pallidal stimulation for pantothenate kinase-associated neurodegeneration dystonia. Archives of Disease in Childhood 2008, 93:239-240.
34. Koeppen A.H., Dickson A.C. Iron in the Hallervorden-Spatz syndrome. Pediatric Neurology 2001, 25:148-155.
35. Krause M., Fogel W., Tronnier V., Pohle S., Hörtnagel K., Thyen U., et al. Long-term benefit to pallidal deep brain stimulation in a case of dystonia secondary to pantothenate kinase-associated neurodegeneration. Movement Disorders 2006, 21:2255-2257.
36. Kruer M.C., Hiken M., Gregory A., Malandrini A., Clark D., Hogarth P., et al. Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 2011, 134:947-958.
37. Kuo Y.M., Duncan J.L., Westaway S.K., Yang H., Nune G., Xu E.Y., et al. Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia. Human Molecular Genetics 2005, 14:49-57.
38. Kurian M.A., Morgan N.V., MacPherson L., Foster K., Peake D., Gupta R., et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008, 70:1623-1629.
39. Li A., Paudel R., Johnson R., Courtney R., Lees A.J., Holton J.L., et al. Pantothenate kinase-associated neurodegeneration is not a synucleinopathy. Neuropathology and Applied Neurobiology 2012, 39:121-131.
40. Lim B.C., Ki C.S., Cho A., Hwang H., Kim K.J., Hwang Y.S., et al. Pantothenate kinase-associated neurodegeneration in Korea: Recurrent R440P mutation in PANK2 and outcome of deep brain stimulation. European Journal of Neurology 2012, 4:556-561.
41. Maawali A.L., Yoon G., Halliday W., Clarke A.T.R., Feigenbaum A., Banwell B., et al. Hypertrophy of the clava, a new MRI sign in patients with PLA2G6 mutations 2011.
42. Mahoney R., Selway R., Lin J.P. Cognitive functioning in children with pantothenate kinase-associated neurodegeneration undergoing deep brain stimulation. Developmental Medicine and Child Neurology 2011, 53:275-279.
43. Malandrini A., Cavallaro T., Fabrizi G.M., Berti G., Salvestroni R., Salvadori C. Ultrastructure and immunoreactivity of dystrophic axons indicate a different pathogenesis of Hallervorden-Spatz disease and infantile neuroaxonal dystrophy. Virchows Archiv 1995, 427:415-421.
44. McNeill A., Birchall D., Hayflick S.J., Gregory A., Schenk J.F., Zimmerman E.A., et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008, 70:1614-1619.
45. Mikata M.A., Yehya A., Darwish H., Karam P., Comair Y. Deep brain stimulation as a mode of treatment of early onset pantothenate kinase-associated neurodegeneration. European Journal of Paediatric Neurology 2009, 13:61-64.
46. Molinuevo J.L., Marti M.J., Blesa R., Tolosa E. Pure akinesia: An unusual phenotype of Hallervorden-Spatz syndrome. Movement Disorders 2003, 18:1351-1353.
47. Morgan N.V., Westaway S.K., Morton J.E., Gregory A., Gissen P., Sonek S., et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nature Genetics 2006, 38:752-754.
48. Mubaidin A., Roberts E., Hampshire D., Dehyyat M., Shurbaji A., Mubaidien M., et al. Karak syndrome: A novel degenerative disorder of the basal ganglia and cerebellum. Journal of Medical Genetics 2003, 40:543-546.
49. Nardocci N., Zorzi G., Farina L., Binelli S., Scaioli W., Ciano C., et al. Infantile neuroaxonal dystrophy: Clinical spectrum and diagnostic criteria. Neurology 1999, 52:1472-1478.
50. Paisan-Ruiz C., Bhatia K.P., Li A., Hernandez D., Davis M., Wood N.W., et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Annals of Neurology 2009, 65:19-23.
51. Paisán-Ruiz C., Li A., Schneider S.A., Holton J.L., Johnson R., Kidd D., et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiology of Aging 2012, 33:814-823.
52. Pellecchia M.T., Valente E.M., Cif L., Salvi S., Albanese A., Scarano V., et al. The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology 2005, 64:1810-1812.
53. Rana A., Seinen E., Siudeja K., Muntendam R., Srinivasan B., van der Want J.J., et al. Pantethine rescues a Drosophila model for pantothenate kinase-associated neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:6988-6993.
54. Rump P., Lemmink H.H., Verschuuren-Bemelmans C.C., Grootscholten P.M., Fock J.M., Hayflick S.J., et al. A novel 3-bp deletion in the PANK2 gene of Dutch patients with pantothenate kinase-associated neurodegeneration: Evidence for a founder effect. Neurogenetics 2005, 6:201-207.
55. Scarano V., Pellecchia M.T., Filla A., Barone P. Hallervorden-Spatz syndrome resembling a typical Tourette syndrome. Movement Disorders 2002, 17:618-620.
56. Schneider S.A., Bhatia K.P. Rare causes of dystonia parkinsonism. Current Neurology and Neuroscience Reports 2010, 10:431-439.
57. Seitelberger F. Eine unbekannte Form von infantiler lipoid-Speicher Krankheit des Gehirns 1952.
58. Shevell M. Hallervorden and history. New England Journal of Medicine 2003, 348:3-4.
59. Shields D.C., Sharma N., Gale J.T., Eskandar E.N. Pallidal stimulation for dystonia in pantothenate kinase-associated neurodegeneration. Pediatric Neurology 2007, 37:442-445.
60. Strecker K., Hesse S., Wegner F., Sabri O., Schwarz J., Schneider J.P. Eye of the tiger sign in multiple systems atrophy. European Journal of Neurology 2007, 14:e1-e2.
61. Swaiman K.F. Hallervorden-Spatz syndrome. Pediatric Neurology 2001, 25:102-108.
62. Timmermann L., Pauls K.A., Wieland K., Jech R., Kurlemann G., Sharma N., et al. Dystonia in neurodegeneration with brain iron accumulation: Outcome of bilateral pallidal stimulation. Brain 2010, 133:701-712.
63. Wada H., Kojo S., Seino K.I. Mouse models of human INAD by Pla2g6 deficiency. Histology and Histopathology 2013, 28:965-969.
64. Wu Y., Jiang Y., Gao Z., Wang J., Yuan Y., Xiong H., et al. Clinical study and PLA2G6 mutation screening analysis in Chinese patients with infantile neuroaxonal dystrophy. European Journal of Neurology 2009, 16:240-245.
65. Yamashita S., Maeda Y., Ohmori H., Uchida Y., Hirano T., Yonemura K., et al. Pantothenate kinase-associated neurodegeneration initially presenting as postural tremor alone in a Japanese family with homozygous N245S substitutions in the pantothenate kinase gene. Journal of Neurological Sciences 2004, 225:129-133.
66. Yang E.Y., Campbell A., Bondy S.C. Configuration of thiols dictates their ability to promote iron-induced reactive oxygen species generation. Redox Report 2000, 5:371-375.
67. Yoon S.J., Koh Y.H., Floyd R.A., Park J.W. Copper, zinc superoxide dismutase enhances DNA damage and mutagenicity induced by cysteine/iron. Mutation Research 2000, 448:97-104.
68. Yoshino H., Tomiyama H., Tachibana N., Ogaki K., Li Y., Funayama M., et al. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 2010, 75:1356-1361.
69. Zhang Y.M., Rock C.O., Jackowski S. Biochemical properties of human pantothenate kinase 2 isoforms and mutations linked to pantothenate kinase-associated neurodegeneration. Journal of Biological Chemistry 2006, 281:107-114.
70. Zhou B., Westaway S.K., Levinson B., Johnson M.A., Gitschier J., Hayflick S.J. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nature Genetics 2001, 28:345-349.
71. Zorzi G., Zibordi F., Chiapparini L., Bertini E., Russo L., Piga A., et al. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial. Movement Disorders 2011, 26:1756-1759.